Pyridostatin

• Description:

  Pyridostatin (RR82) is a G-quadruplex DNA stabilizing agent (Kd=490 nM) and can target DNA and RNA G4s in cells. Pyridostatin promotes growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage. Pyridostatin targets the proto-oncogene Src. Pyridostatin reduced SRC protein levels and SRC-dependent cellular motility in human breast cancer cells[1][2].

• Product Name Alternative:

  RR82

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  G-quadruplex

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Pyridostatin.html

• Purity:

  96.03

• Solubility:

  DMSO : 100 mg/mL

• Smiles:

  O=C(C1=CC(OCCN)=CC(C(NC2=NC3=C(C(OCCN)=C2)C=CC=C3)=O)=N1)NC4=CC(OCCN)=C5C=CC=CC5=N4

• Molecular Formula:

  C31H32N8O5

• Molecular Weight:

  596.64

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Rodriguez R, et al. Small-molecule-induced DNA damage identifies alternative DNA structures in human genes. Nat Chem Biol. 2012;8 (3) :301-310. Published 2012 Feb 5.|[2]Koirala D, et al. A single-molecule platform for investigation of interactions between G-quadruplexes and small-molecule ligands. Nat Chem. 2011;3 (10) :782-787. Published 2011 Aug 28.|[3]Moruno-Manchon JF, Koellhoffer EC, Gopakumar J, et al. The G-quadruplex DNA stabilizing drug pyridostatin promotes DNA damage and downregulates transcription of Brca1 in neurons. Aging (Albany NY) . 2017;9 (9) :1957-1970.|[4]Zhang X, et al. Chemical profiling of DNA G-quadruplex-interacting proteins in live cells. Nat Chem. 2021 Jul;13 (7) :626-633.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Citation 01:

  ACS Omega. 2023 Sep 25;8 (40) :37369-37373.|Anal Chem. 2025 Jun 10;97 (22) :11617-11626.|Biochem Mol Biol Educ. 2020 Jul;48 (4) :329-336.|Int J Biol Macromol. 2021 Nov 1:190:178-188.|Int J Biol Macromol. 2025 Jun 20;319 (Pt 1) :145405.|iScience. 2022 Oct 9;25 (11) :105312.|J Med Virol. 2023 Jan;95 (1) :e28299.|J Natl Cancer Inst. 2023 Nov 8;115 (11) :1383-1391.|Nucleic Acids Res. 2019 Aug 22;47 (14) :7306-7320.|Nucleic Acids Res. 2022 Jun 24;50 (12) :6953-6967.|Nucleic Acids Res. 2024 Mar 21;52 (5) :2142-2156.|Biochemistry. 2024 Oct 15;63 (20) :2609-2620.|Biol Pharm Bull. 2019 May 1;42 (5) :721-727.|bioRxiv. 2025 March 14.|Cancer Res. 2025 Oct 1.|Emerg Microbes Infect. 2025 Jan 2:2447620.|Eur J Med Chem Rep. 2025 Dec.|Int J Biol Macromol. 2025 Jan 31:140556.|J Am Chem Soc. 2021 Dec 15;143 (49) :20779-20791.|J Ethnopharmacol. 2024 Apr 6:323:117694.|J Hepatol. 2020 Aug;73 (2) :371-382.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Med Chem Res. 2024 Nov 14.|Mol Cell. 2024 Jun 6;84 (11) :2070-2086.e20.|Nat Commun. 2022 Mar 17;13 (1) :1444.|Nat Commun. 2022 Sep 16;13 (1) :5456.|Nucleic Acids Res. 2023 Oct 27;51 (19) :10752-10767.|PLoS Pathog. 2023 Jan 26;19 (1) :e1011131.|Redox Biol. 2024 Sep:75:103247.|Nat Chem Biol. 2025 Aug 7.

• CAS Number:

  [1085412-37-8]